Blood test may personalize Post-Surgery cancer care
NCT ID NCT06914011
First seen Jan 02, 2026 · Last updated Jun 14, 2026 · Updated 32 times
Summary
This study tests whether using a blood test to detect leftover cancer DNA can help decide who needs extra chemotherapy after esophageal cancer surgery. About 172 adults with stage 2 or 3 esophageal cancer will be randomly assigned to either standard follow-up or chemotherapy plus an immunotherapy drug (tisleliizumab). The goal is to see if the personalized approach improves the chance of staying cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.